Zacks: Brokerages Set $46.50 Target Price for Natus Medical Inc. (NASDAQ:BABY)
Natus Medical Inc. (NASDAQ:BABY) has been assigned a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. Natus Medical’s rating score has improved by 20.4% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Brokers have set a twelve-month consensus target price of $46.50 for the company and are predicting that the company will post $0.42 EPS for the current quarter, according to Zacks. Zacks has also assigned Natus Medical an industry rank of 91 out of 265 based on the ratings given to its competitors.
BABY has been the topic of a number of recent analyst reports. Raymond James Financial Inc. upgraded Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target on the stock in a report on Tuesday, September 13th. Zacks Investment Research upgraded Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a report on Thursday, July 7th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/zacks-brokerages-set-46-50-target-price-for-natus-medical-inc-nasdaqbaby.html
A number of hedge funds have recently added to or reduced their stakes in BABY. Norges Bank purchased a new stake in Natus Medical during the fourth quarter worth about $15,163,000. Moody Aldrich Partners LLC purchased a new stake in Natus Medical during the first quarter worth about $591,000. Apex Capital Management increased its stake in Natus Medical by 19.5% in the first quarter. Apex Capital Management now owns 381,746 shares of the company’s stock worth $14,670,000 after buying an additional 62,350 shares in the last quarter. Aperio Group LLC increased its stake in Natus Medical by 37.3% in the first quarter. Aperio Group LLC now owns 8,823 shares of the company’s stock worth $339,000 after buying an additional 2,398 shares in the last quarter. Finally, Pacad Investment Ltd. purchased a new stake in Natus Medical during the first quarter worth about $284,000. 87.92% of the stock is owned by institutional investors and hedge funds.
Natus Medical (NASDAQ:BABY) traded down 0.69% on Wednesday, hitting $42.90. The company’s stock had a trading volume of 52,382 shares. The stock has a market cap of $1.39 billion, a PE ratio of 36.98 and a beta of 0.85. Natus Medical has a 12 month low of $29.54 and a 12 month high of $51.05. The firm has a 50 day moving average of $39.78 and a 200-day moving average of $36.64.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, July 20th. The company reported $0.39 EPS for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.03. The business had revenue of $96 million for the quarter, compared to analyst estimates of $92.71 million. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. Natus Medical’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the company posted $0.34 earnings per share. On average, analysts expect that Natus Medical will post $1.70 earnings per share for the current fiscal year.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.